Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318575182> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4318575182 endingPage "i810" @default.
- W4318575182 startingPage "i808" @default.
- W4318575182 abstract "Abstract Background Crohn’s disease (CD) is an incurable chronic inflammatory condition of the gut. It causes severe gastrointestinal and extraintestinal complications and is associated with high morbidity, poor quality of life and increased health expenditure. Although increasing randomized controlled tests (RCT) studies demonstrated the premise of efficacy of biologics including vedolizumab in adult patients with active CD, there’re still 60% of patients hard to achieve clinical and endoscopic remission in real-world studies. Here, we investigated the efficacy of combination strategy of vedolizumab and exclusive enteral nutrition (EEN) in moderate to severe active CD treatment. Methods Twenty-eight patients with moderately to severely active CD patients treated with vedolizumab in IBD medical center of Renmin Hospital of Wuhan University in Hubei Province were retrospectively enrolled in this cohort. All patients received EEN for 16 weeks with concomitant vedolizumab standard induction. The clinical response, clinical remission, and fecal calprotectin (FC) normalization was evaluated in short- (week 16) and moderate-term (week 32 and 48). Endoscopic response and mucosal healing were assessed at week 16 and 48 (Figure 1). Figure 1: Study design Results Following vedolizumab intravenous induction and 16-weeks EEN treatment, patients achieved 71.4% (20/28) of clinical remission, 73.1% (19/26) of endoscopic response and 71.4% (20/28) FC normalization at week 16. For moderate-term assessment at week 32, sustainable efficacy of current treatment induced 19/24 (79.2%) of clinical response, 15/24 (62.5%) of clinical remission and 16/24 (66.7%) of FC normalization. Clinical response (15/22, 68.2%) and mucosa healing (14/22, 63.6%) were also observed in over 60% of patients at week 48 since treatment induction (Figure 2,3). Figure 2. Clinical and biochemical endpoints Figure 3. Endoscopic endpoint Conclusion Combination of Vedolizumab and 16-weeks EEN increased clinical and endoscopic outcomes in short and moderate term for patients with moderate to severe Crohn’s Disease." @default.
- W4318575182 created "2023-01-31" @default.
- W4318575182 creator A5001474860 @default.
- W4318575182 creator A5007469636 @default.
- W4318575182 creator A5008668422 @default.
- W4318575182 creator A5014300282 @default.
- W4318575182 creator A5057557742 @default.
- W4318575182 creator A5064335773 @default.
- W4318575182 creator A5069924097 @default.
- W4318575182 creator A5080754945 @default.
- W4318575182 creator A5083531652 @default.
- W4318575182 creator A5085683795 @default.
- W4318575182 creator A5088433134 @default.
- W4318575182 date "2023-01-30" @default.
- W4318575182 modified "2023-10-15" @default.
- W4318575182 title "P677 Combination of vedolizumab and exclusive enteral nutrition in patients with moderate to severe Crohn’s Disease" @default.
- W4318575182 doi "https://doi.org/10.1093/ecco-jcc/jjac190.0807" @default.
- W4318575182 hasPublicationYear "2023" @default.
- W4318575182 type Work @default.
- W4318575182 citedByCount "0" @default.
- W4318575182 crossrefType "journal-article" @default.
- W4318575182 hasAuthorship W4318575182A5001474860 @default.
- W4318575182 hasAuthorship W4318575182A5007469636 @default.
- W4318575182 hasAuthorship W4318575182A5008668422 @default.
- W4318575182 hasAuthorship W4318575182A5014300282 @default.
- W4318575182 hasAuthorship W4318575182A5057557742 @default.
- W4318575182 hasAuthorship W4318575182A5064335773 @default.
- W4318575182 hasAuthorship W4318575182A5069924097 @default.
- W4318575182 hasAuthorship W4318575182A5080754945 @default.
- W4318575182 hasAuthorship W4318575182A5083531652 @default.
- W4318575182 hasAuthorship W4318575182A5085683795 @default.
- W4318575182 hasAuthorship W4318575182A5088433134 @default.
- W4318575182 hasBestOaLocation W43185751821 @default.
- W4318575182 hasConcept C126322002 @default.
- W4318575182 hasConcept C168563851 @default.
- W4318575182 hasConcept C2776207728 @default.
- W4318575182 hasConcept C2778260677 @default.
- W4318575182 hasConcept C2778292693 @default.
- W4318575182 hasConcept C2779008522 @default.
- W4318575182 hasConcept C2779134260 @default.
- W4318575182 hasConcept C2779280984 @default.
- W4318575182 hasConcept C2779384505 @default.
- W4318575182 hasConcept C2780479503 @default.
- W4318575182 hasConcept C71924100 @default.
- W4318575182 hasConcept C78722104 @default.
- W4318575182 hasConcept C90924648 @default.
- W4318575182 hasConceptScore W4318575182C126322002 @default.
- W4318575182 hasConceptScore W4318575182C168563851 @default.
- W4318575182 hasConceptScore W4318575182C2776207728 @default.
- W4318575182 hasConceptScore W4318575182C2778260677 @default.
- W4318575182 hasConceptScore W4318575182C2778292693 @default.
- W4318575182 hasConceptScore W4318575182C2779008522 @default.
- W4318575182 hasConceptScore W4318575182C2779134260 @default.
- W4318575182 hasConceptScore W4318575182C2779280984 @default.
- W4318575182 hasConceptScore W4318575182C2779384505 @default.
- W4318575182 hasConceptScore W4318575182C2780479503 @default.
- W4318575182 hasConceptScore W4318575182C71924100 @default.
- W4318575182 hasConceptScore W4318575182C78722104 @default.
- W4318575182 hasConceptScore W4318575182C90924648 @default.
- W4318575182 hasIssue "Supplement_1" @default.
- W4318575182 hasLocation W43185751821 @default.
- W4318575182 hasOpenAccess W4318575182 @default.
- W4318575182 hasPrimaryLocation W43185751821 @default.
- W4318575182 hasRelatedWork W2090228779 @default.
- W4318575182 hasRelatedWork W2326791703 @default.
- W4318575182 hasRelatedWork W2415541294 @default.
- W4318575182 hasRelatedWork W2529617706 @default.
- W4318575182 hasRelatedWork W2603062471 @default.
- W4318575182 hasRelatedWork W2982020561 @default.
- W4318575182 hasRelatedWork W3116505544 @default.
- W4318575182 hasRelatedWork W3122917925 @default.
- W4318575182 hasRelatedWork W3180056052 @default.
- W4318575182 hasRelatedWork W4310736446 @default.
- W4318575182 hasVolume "17" @default.
- W4318575182 isParatext "false" @default.
- W4318575182 isRetracted "false" @default.
- W4318575182 workType "article" @default.